PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Table 1 Demographics and clinical characteristics of patients in the CIK treatment and Control groups

Clinicopathologic variables	Control Group (n = 160)	CIK Treatment Group (n = 150)	p value
Age (y)			0.685
< 50	59	52
≥ 50	101	98
Tumor size (mm)			0.500
< 20	76	77
≥ 20	84	73
TNM stage			0.849
I	19	15
II	66	65
III	75	70
Histological differentiation			0.905
I/II	96	89
III	64	61
Positive lymph node ratio			0.628
< 0.21	59	50
0.21 ≤ x < 0.65	80	75
≥0.65	21	25
Receptor status
ER			0.602
Positive	51	52
Negative	109	98
PR			0.877
Positive	75	69
Negative	85	81
Her2			0.604
Positive	60	52
Negative	100	98
PD-L1 expression			0.264
Positive	42	44
Negative	118	106
Chemotherapy			0.549
Yes	150	138
No	10	12
Radiotherapy			0.267
Yes	149	144
No	11	6
Endocrinetherapy			0.136
Yes	109	90
No	51	60
TNBC			0.952
Yes	26	24
No	134	126